The Wall Street Journal • 6 hours ago
Merck posted an unexpected increase in second-quarter revenue thanks to new cancer and hepatitis treatments, and an increased profit versus a year-earlier period that was weighed down by foreign-exchange ...
The Wall Street Journal • yesterday
Bristol-Myers Squibb said its second-quarter revenue rose 17%, again driven by the growth of the pharmaceutical company’s Opdivo cancer immunotherapy and other key drugs.
Reuters • yesterday
Bristol-Myers Squibb Co reported disappointing second-quarter sales of its Yervoy melanoma treatment on Thursday, raising concerns about the long-term prospects for one of its most important cancer medicines ...
Zacks • yesterday
Bristol-Myers' (BMY) delivered better-than-expected second-quarter 2016 earnings and revenues; it raised the 2016 earnings outlook yet again.
24/7 Wall St. • yesterday
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
Bristol-Myers Squibb CompanyNYSE
After hours: 74.79-0.01 (-0.02%) as of 4:49 PM EDT
|Bid||74.72 x 100|
|Ask||74.98 x 100|
|52wk Range||51.82 - 77.12|
|Day's Range||74.22 - 75.16|
|Avg Vol (3m)||5,786,747|
As of 4:00 PM EDT. Market closed.